Key Finding: Regulatory Agencies Split on New Alzheimer’s Drugs as Hope Meets Uncertainty

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Regulatory agencies reviewing Alzheimer's disease treatment approvals with conflicting decisions
Regulatory agencies worldwide are delivering conflicting assessments of novel Alzheimer's treatments, creating uncertainty for millions of patients. The Lancet examines divergent approval pathways and their implications for global access. — Photo: SHVETS production / Pexels
1 min read|38 words

55 million people worldwide live with dementia, yet new Alzheimer's treatments face conflicting regulatory decisions across different countries. Some agencies approve based on biomarker changes while others demand functional improvement evidence.

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Celebrity Disclosure Renews Focus on Prostate Cancer Screening and Early Detection

Television presenter Jeremy Clarkson's recent disclosure of aggressive prostate cancer and remission…

Magnesium Supplement Claims vs. Evidence: What the Science Actually Shows

Animal studies show tissue-specific magnesium uptake, but human trials have not replicated…

Biology’s Universal Blueprint: How Cells Reveal the Mechanics of Life

All living organisms operate according to shared cellular principles—membrane structure, energy metabolism,…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like